Business Wire - December 9, 2005
The first presentation, "Safety and Antiviral Activity of PA-457, the First-In-Class Maturation Inhibitor, in a 10-Day Monotherapy Study in HIV-1 Infected Patients," will be given by George Beatty, M.D., Assistant Clinical Professor, Medicine; Director, HIV Clinical Trials Unit, UCSF Positive Health Program at San Francisco General Hospital; and investigator in the PA-457 Phase 2a trial. This late-breaker presentation will be held on Friday, December 16, 2005 at 4:15 p.m. EST.
The second presentation, "PKPD Modeling & Simulation of PA-457 from a Single Dose Viral Dynamic Study in HIV-Infected Patients," will be given by Patrick F. Smith, Pharm.D., Associate Professor in the School of Pharmacy and Pharmaceutical Sciences, at the University at Buffalo. The presentation will be held on Saturday, December 17, 2005 at 2:30 p.m. EST.
Further information about ICAAC can be found at www.icaac.org.
About Panacos
Panacos is developing the next generation of anti-infective products through discovery and development of small molecule oral drugs for the treatment of HIV and other major human viral diseases. Panacos' lead candidate, PA-457, is the first in a new class of oral HIV therapeutics under development called maturation inhibitors, discovered by Panacos scientists and their academic collaborators. By targeting a novel step in the virus life cycle, maturation inhibitors are designed to have potent activity against a broad range of HIV, including strains that are resistant to existing classes of drugs. Drug resistance is the most pressing problem in HIV therapy and the leading cause of treatment failure. Panacos' proprietary discovery technologies focus on novel targets in the virus life cycle, including virus maturation and virus fusion.
Except for the historical information contained herein, statements made herein are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements involve risks as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.
CONTACT: Panacos Pharmaceuticals, Inc.
Jill Smith, 240-449-1250, jsmith@panacos.com
or
Peyton Marshall, 617-926-1551, pmarshall@panacos.com
SOURCE: Panacos Pharmaceuticals, Inc.
051209
BW051213
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .